The patents cover psychedelic-based therapeutics, including monotherapy. “We have great confidence in our collaboration with Clearmind," SpiSparc CEO Oz Adler says. Get access to the leaderboards ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback